Generic Hyplon ( Zaleplon )

Buy Generic Hyplon (Zaleplon) without prescription in Canada

In our Canadian pharmacy, you can buy Hyplon (Zaleplon) without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Hyplon (zaleplon) is a non‑benzodiazepine hypnotic agent of the pyrazolopyrimidine class, commonly referred to as a “Z‑drug.” It is used for the short‑term treatment of insomnia characterised by difficulty falling asleep. Zaleplon works by selectively binding to the benzodiazepine site on the GABA_A receptor complex, particularly those containing the α1 subunit, which facilitates inhibitory neurotransmission in the brain and helps to rapidly induce sleep. Its unique pharmacokinetic profile provides a very fast onset of sleep with a short duration of action, minimising next‑day residual sedation when taken as directed.

Usual adult dose: The recommended dose is 10 mg taken orally just before bedtime or after going to bed and experiencing difficulty falling asleep. The dose should be taken only if the patient is able to remain in bed for a full night’s sleep of at least 4 hours. A lower dose of 5 mg is recommended for elderly patients, those with mild to moderate hepatic impairment, and those who are debilitated or sensitive to the effects of hypnotics. The total daily dose should not exceed 10 mg. Do not take a second dose during the same night.

Dosage form: Oral capsule containing 10 mg of zaleplon. In Canada, the identical active ingredient is marketed under the brand name Starnoc in 5 mg and 10 mg capsules.

Onset of action: Zaleplon is rapidly absorbed, reaching peak plasma concentrations within approximately 1 hour. Sleep is typically induced within 15 to 30 minutes of taking the dose on an empty stomach.

Duration of action: Zaleplon has a very short elimination half‑life of approximately 1 hour. Its clinical effect lasts for about 3 to 4 hours, allowing for sleep initiation without significant morning hangover.

Alcohol recommendation: Alcohol consumption must be strictly avoided during treatment with Hyplon. Alcohol and zaleplon both depress the central nervous system, and their combined use can cause profound sedation, severely impaired coordination, respiratory depression, and an increased risk of dangerous complex sleep‑related behaviours.

Most common side effects: Headache, dizziness, nausea, and somnolence. Uncommon but significant effects include anterograde amnesia (forgetting events that occur after taking the dose), confusion, and hallucinations. Complex sleep‑related behaviours such as sleep‑walking, sleep‑driving, preparing and eating food, or making phone calls with no memory of the event have been reported. These behaviours can occur at therapeutic doses and are more likely when the medication is combined with alcohol or other CNS depressants.

Would you like to try Hyplon (Zaleplon) without a prescription?

General Information about Hyplon (Zaleplon)

• INN (International Nonproprietary Name): Zaleplon
• Brand names available in Canada: The brand name Hyplon is not approved for marketing in Canada. The active ingredient zaleplon is legally available in Canada under the brand name Starnoc® (Valeant Canada LP / Bausch Health, Canada Inc.) in 5 mg and 10 mg capsules. No generic formulations are currently marketed. Hyplon is an internationally sourced product obtained by our pharmacy through the international supply chain for personal importation.
• ATC code: N05CF03 (zaleplon; benzodiazepine‑related drugs).
• Dosage forms and strengths: Oral capsules: 10 mg (Hyplon). In Canada, Starnoc is available as 5 mg and 10 mg capsules.
• Manufacturers in Canada: Valeant Canada LP / Bausch Health, Canada Inc. (Starnoc). No manufacturer in Canada produces the Hyplon brand; it is manufactured internationally and imported for personal use.
• Registration status in Canada: Approved by Health Canada for the active ingredient zaleplon (Starnoc). The specific Hyplon brand is not marketed in Canada and has not been issued a Notice of Compliance. Starnoc DINs: 02248247 (5 mg), 02248248 (10 mg).
• OTC / Rx classification: Prescription only (Rx). Zaleplon is a Schedule IV controlled substance under the Controlled Drugs and Substances Act. It is available only with a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Zaleplon is a non‑benzodiazepine hypnotic that belongs to the pyrazolopyrimidine class. Although structurally unrelated to benzodiazepines, it exerts its therapeutic effect by selectively binding to the benzodiazepine (BZ) recognition site of the GABA_A receptor complex. Zaleplon preferentially interacts with GABA_A receptors containing the α1 subunit (the BZ‑1 receptor subtype), which are thought to mediate the sedative and hypnotic effects. By enhancing the affinity of the inhibitory neurotransmitter gamma‑aminobutyric acid (GABA) for its receptor, zaleplon increases the frequency of chloride channel opening, resulting in neuronal hyperpolarisation and a reduction in neuronal excitability. Its very short elimination half‑life of approximately 1 hour and rapid absorption make it uniquely suited for sleep‑initiation insomnia, reducing the likelihood of next‑day residual effects. The drug is metabolised primarily by aldehyde oxidase and, to a lesser extent, by cytochrome P450 3A4, to inactive metabolites excreted mainly in the urine.

Indications

• Short‑term treatment of insomnia in adults, specifically for the management of difficulty falling asleep (sleep‑onset insomnia). It is generally prescribed for a duration of 7 to 10 days, and prolonged use should be re‑evaluated by a physician.
• Zaleplon should only be used when the patient is able to dedicate a full night (at least 4 hours) to sleep.
• It is not indicated for the treatment of sleep maintenance insomnia (difficulty staying asleep) or early morning awakenings.
• Not recommended for use in children and adolescents under 18 years of age; safety and efficacy have not been established in this population.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Zaleplon should not be used during pregnancy. There are no adequate and well‑controlled studies in pregnant women. Infants born to mothers who took sedative‑hypnotics late in the third trimester may be at risk for sedation and withdrawal symptoms.
• Breastfeeding: Zaleplon is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment.
• Paediatrics (< 18 years): Safety and efficacy have not been established. Zaleplon is not indicated for use in children and adolescents.
• Elderly (> 65 years): Elderly patients are particularly sensitive to the effects of hypnotics, including sedation, dizziness, and complex sleep‑related behaviours. The recommended dose for elderly patients is 5 mg. The 10 mg dose should be used only if clinically necessary and tolerated.
• Hepatic impairment: The oral clearance of zaleplon is reduced by 70% to 87% in patients with compensated and decompensated cirrhosis. The recommended dose for patients with mild to moderate hepatic impairment is 5 mg. Zaleplon is not recommended in patients with severe hepatic impairment.
• Renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Zaleplon has not been adequately studied in patients with severe renal impairment.
• Respiratory impairment: Sedative‑hypnotics have the capacity to depress respiratory drive. Caution is advised when administering zaleplon to patients with compromised respiratory function, such as those with sleep apnoea, myasthenia gravis, or severe chronic obstructive pulmonary disease.
• Depression and suicidality: Zaleplon may worsen depression or unmask suicidal ideation. It should be used with caution in patients with a history of depression. Intentional overdose is more common in this group, and the smallest feasible quantity should be prescribed.
• History of substance abuse: Zaleplon has a potential for abuse and dependence. It should be used with extreme caution in patients with a personal or family history of drug or alcohol abuse.
• Complex sleep‑related behaviours: Serious behaviours such as sleep‑walking, sleep‑driving, making phone calls, and preparing/eating food while not fully awake have been reported. These events can occur with therapeutic doses and without a history of such behaviours. Discontinuation should be strongly considered for any patient who experiences a complex sleep behaviour. The risk is significantly increased with concurrent alcohol or CNS depressant use.
• Allergy: Do not take Hyplon if you have a known hypersensitivity to zaleplon or any component of the formulation.

Driving and alcohol

Hyplon can cause significant psychomotor impairment, including dizziness, somnolence, and decreased alertness. Patients must not drive a motor vehicle or operate heavy machinery for at least 4 hours after taking zaleplon, or until they feel fully awake and alert. Alcohol consumption must be strictly avoided during treatment. The combination of alcohol and zaleplon can cause profound sedation, dangerously slow or stopped breathing, and fatal complex sleep‑related behaviours.

Dosage Instructions

• Standard adult dose (under 65 years): The recommended dose is 10 mg taken orally just before bedtime or after the patient has gone to bed and has experienced difficulty falling asleep. Do not take with or immediately after a heavy, high‑fat meal, as this will significantly delay absorption and onset of action. The total daily dose should not exceed 10 mg. Do not take a second dose during the same night.
• Elderly, debilitated, or hepatically impaired patients: The recommended dose is 5 mg. The 10 mg dose should only be used if the lower dose is ineffective and the patient does not experience dose‑limiting side effects.
• Administration: Take the capsule with a glass of water on an empty stomach for fastest effect. If taken with food, the onset of action may be delayed by up to 2 hours.
• Missed dose: Zaleplon is taken only as needed, not on a fixed nightly schedule. Do not take a dose if you do not have at least 4 hours remaining before your planned awakening.
• Duration of therapy: The lowest effective dose should be used. Treatment should be as short as possible, generally not exceeding 7 to 10 days. The need for continued treatment beyond 2 weeks should be re‑evaluated by a physician. Long‑term use is not recommended due to the risks of tolerance and dependence.
• Discontinuation: When the drug has been used nightly for a prolonged period, gradual dose reduction is recommended to minimise the risk of rebound insomnia and withdrawal symptoms.

Side Effects and Contraindications

• Common side effects (≥ 1%): Headache, dizziness, nausea, somnolence, and abdominal pain. Amnesia, confusion, and difficulty concentrating may also occur.
• Uncommon but serious side effects: Complex sleep‑related behaviours (sleep‑driving, sleep‑walking, eating while asleep), hallucinations, agitation, and aggressive behaviour. Anterograde amnesia can occur even at therapeutic doses; this risk is increased with alcohol.
• Dependence and withdrawal: Physical and psychological dependence can develop, particularly with prolonged use. Withdrawal symptoms (including rebound insomnia, anxiety, tremor, and rarely seizures) can occur upon abrupt discontinuation.
• Contraindications: Known hypersensitivity to zaleplon or any excipient in the formulation. Severe hepatic impairment. Pre‑existing sleep apnoea, myasthenia gravis, severe respiratory insufficiency, or a history of complex sleep‑related behaviours while taking sedative‑hypnotic drugs. Pregnancy and breastfeeding.

Drug Interactions

• Central nervous system (CNS) depressants: Alcohol, benzodiazepines, opioids, tricyclic antidepressants, and other sedating drugs cause additive psychomotor impairment, respiratory depression, and increase the risk of complex sleep‑related behaviours. This combination should be avoided or carefully monitored.
• Strong CYP3A4 inducers: Drugs such as rifampin, carbamazepine, and phenytoin can significantly reduce zaleplon plasma concentrations, potentially reducing its hypnotic efficacy. A dose increase may be necessary.
• CYP3A4 inhibitors: Cimetidine and erythromycin can increase zaleplon plasma concentrations, increasing the risk of side effects. A dose reduction to 5 mg may be required.
• Opioid analgesics: The concomitant use of opioids and sedative‑hypnotics like zaleplon increases the risk of profound sedation, respiratory depression, coma, and death. These medications should only be co‑prescribed when no other alternatives are available, at the lowest effective doses, and for the shortest possible duration.

Practical Advice

• Administration: Take Hyplon exactly as prescribed. Take the capsule with water just before you get into bed, or after you are in bed and have difficulty falling asleep. Do not take it with a heavy, high‑fat meal, as this will slow its effect significantly. Do not take a second dose in the same night, even if you wake up later.
• Monitoring: Your doctor will periodically reassess the need for continued treatment. Report any episodes of memory loss (amnesia), hallucinations, agitation, or complex sleep behaviours (like getting out of bed while not fully awake) immediately. Be alert for signs of misuse or dependence.
• Storage: Store at room temperature (15‑30 °C), protected from light and moisture. Keep out of the reach and sight of children. Because of the risk of diversion and misuse, store in a secure location.
• Lifestyle: Practise good sleep hygiene: maintain a consistent sleep schedule, avoid caffeine and heavy meals in the evening, and create a cool, dark, quiet sleep environment. Use this medication only when you have a full 4 hours available for sleep. Do not drink alcohol.
• When to seek medical review: Discontinue Hyplon and seek immediate medical attention if you experience a complex sleep behaviour (sleep‑driving, sleep‑walking, making calls while asleep), a severe allergic reaction (difficulty breathing, swelling of the face or throat), or thoughts of harming yourself or others. If you have been taking the medication regularly, do not stop abruptly; consult your doctor for a tapering schedule.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Zopiclone (Imovane®): A widely available Z‑drug in Canada for short‑term insomnia. It has a longer half‑life than zaleplon and is effective for both sleep onset and sleep maintenance, but it carries a higher risk of morning impairment and taste disturbance.
• Eszopiclone (Lunesta®): A stereo‑isomer of zopiclone, not currently marketed in Canada, though it is available in the United States. It has a longer duration of action.
• Benzodiazepines (e.g., Temazepam, Lorazepam): Effective for insomnia but carry a much higher risk of physical dependence, withdrawal, and next‑day sedation, and are generally reserved for short‑term use when other treatments have failed.
• Melatonin and melatonin receptor agonists (e.g., Ramelteon): Melatonin helps regulate the circadian rhythm and is available over the counter. Ramelteon (Rozerem®) is a prescription melatonin receptor agonist with no abuse potential, specifically indicated for sleep‑onset insomnia; it is not widely marketed in Canada.
• Orexin receptor antagonists (e.g., Suvorexant, Lemborexant): A newer class of hypnotics that block the brain’s wakefulness signal. They are not controlled substances and have a lower risk of dependence; lemborexant (Dayvigo®) is available in Canada.
• Cognitive behavioural therapy for insomnia (CBT‑I): The first‑line treatment for chronic insomnia, focusing on changing the thoughts and behaviours that disrupt sleep. CBT‑I is effective without the risks associated with medication and is recommended by the Canadian Sleep Society.

Clinical Efficacy

Zaleplon has been proven effective in reducing the time it takes to fall asleep (sleep latency) in numerous randomised, double‑blind, placebo‑controlled trials. In a systematic review of studies involving zaleplon, doses of 5 mg, 10 mg, and 20 mg significantly reduced sleep latency compared with placebo. The 10 mg dose produced a median reduction in sleep onset of approximately 10 to 20 minutes. The medication’s very short half‑life means it does not significantly prolong total sleep time or reduce nighttime awakenings, and it is associated with minimal next‑day residual sedation when taken as prescribed. Zaleplon is also effective when taken in the middle of the night, provided the patient has at least 4 hours remaining in bed, with no increase in morning impairment. Its safety and efficacy profile make it a useful option for patients who primarily have trouble falling asleep but can stay asleep once they do.

Important:

Hyplon (zaleplon) is a prescription sedative‑hypnotic medication that should be used only under the supervision of a qualified healthcare professional. It can cause dangerous complex sleep‑related behaviours, including sleep‑driving, that can lead to serious injury or death. Patients who experience such an event must stop taking the medication immediately and seek medical attention. Do not take zaleplon with alcohol, opioids, or other central nervous system depressants, as this combination significantly increases the risk of these behaviours and profound respiratory depression. This medication can impair driving and motor skills; do not drive for at least 4 hours after taking a dose or until you are fully awake. Tolerance, dependence, and withdrawal symptoms can occur, especially with prolonged use. Zaleplon is contraindicated during pregnancy and breastfeeding. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Hyplon - Shipping across Canada